본문 바로가기
KERD
논문KCI 등재

소아청소년 영역에서의 새로운 항미생물제

New Antimicrobial Agents for Children

은병욱
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)|2009.06|Pediatric Infection and Vaccine|제16권 제1호|pp. 6-12

0

조회

0

다운로드

0

인용

0

참고문헌

초록

Abstract

There are relatively few novel antimicrobial agents despite the dramatic increase in antimicrobial resistance and multiple drug resistance of clinical isolates worldwide. Vancomycin is still the most widely used antibiotic for treating resistant Gram-positive coccal infections in children, especially for methicillin-resistant Staphylococcus aureus. For children with Gram-positive coccal infections where vancomycin is not effective or older therapeutic agents cannot be tolerated, linezolid, quinupristin-dalfopristin or daptomycin may be useful in the appropriate clinical setting. For Gram-negative bacterial infections, new carbapenems await clinical application. Tebipenem pivoxil is a novel oral carbapenem undergoing clinical trials for acute otitis media in pediatric patients. Antiviral drug development is now progressing at the pace of antibiotic development 30 years ago. Newer antiviral agents used for the treatment of herpes viruses and hepatitis C virus infections in children are included in this review.

참고문헌 (41)

  1. Wenzel RP, "The antibiotic pipeline--challenges, costs, and values", N Engl J Med, 351, pp.523~526 (2004)
  2. Kaplan SL, "Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children", Pediatr Infect Dis J, 22, pp.677~686 (2003)
  3. Chen CJ, "Experience with linezolid therapy in children with osteoarticular infections", Pediatr Infect Dis J, 26, pp.985~988 (2007)
  4. Meissner HC, "Hematologic effects of linezolid in young children", Pediatr Infect Dis J, 22(9), pp.S186~S192 (2003)
  5. Saiman L, "Safety and tolerability of linezolid in children", Pediatr Infect Dis J, 22(9), pp.S193~S200 (2003)
  6. Bradley JS, "Newer antistaphylococcal agents", Curr Opin Pediatr, 17, pp.71~77 (2005)
  7. Velissariou IM, "Use of linezolid in children: an overview of recent advances", Expert Rev Anti Infect Ther, 4, pp.947~952 (2006)
  8. Loeffler AM, "Safety and efficacy of quinupristin", dalfopristin for treatment of invasive Gram-positive infections in pediatric patients, 2002, pp.21, 950~956
  9. Hershberger E, "Quinupristin-dalfopristin resistance in grampositive bacteria: mechanism of resistance and epidemiology", Clin Infect Dis, 38, pp.92~98 (2004)
  10. Hancock RE, "Mechanisms of action of newer antibiotics for Gram-positive pathogens", Lancet Infect Dis, 5, pp.209~218 (2005)
  11. Silverman JA, "Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact", J Infect Dis, 191, pp.2149~2152 (2005)
  12. Ardura MI, "Daptomycin therapy for invasive Gram-positive bacterial infections in children", Pediatr Infect Dis J, 26, pp.1128~2232 (2007)
  13. Abdel-Rahman SM, "Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections", Pediatr Infect Dis J, 27, pp.330~334 (2008)
  14. Daptomycin for injection, "Full prescribing reference" (2006), Cubist Pharmaceutical
  15. Shah PM, "Ertapenem, the first of a new group of carbapenems", J Antimicrob Chemother, 52, pp.538~542 (2003)
  16. Fuchs PC, "In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers", Antimicrob Agents Chemother, 45, pp.1915~1918 (2001)
  17. Livermore DM, "In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia", Antimicrob Agents Chemother, 45, pp.1860~1867 (2001)
  18. Zhanel GG, "Ertapenem: review of a new carbapenem", Expert Rev Anti Infect Ther, 3, pp.23~39 (2005)
  19. Yellin AE, "Ertapenem or ticarcillin", clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients, 2007, pp.194, 367~374
  20. "Merck and Co. INVANZⓇ (ertapenem for injection): prescribing information"[URL]
  21. "48th Annual ICCAC", IDSA 46th Annual Meeting (2008)
  22. "48th Annual ICCAC", IDSA 46th Annual Meeting (2008)
  23. Kobayashi R, "In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae", Antimicrob Agents Chemother, 49, pp.889~894 (2005)
  24. Sato N, "Population pharmacokinetics of Tebipenem Pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia", Drug Metab Pharmacokinet, 23, pp.434~446 (2008)
  25. Saez-Llorens X, "De Leon Castrejon T, et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection", Antimicrob Agents Chemother, 53, pp.1912~1920 (2009)
  26. Chakrabarty A, "Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug", Antivir Chem Chemother, 15, pp.251~253 (2004)
  27. Bueno J, "Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients", Paediatr Drugs, 4, pp.279~290 (2002)
  28. Allen UD, "Current status and impact of CMV prevention following pediatric organ transplantation", Pediatr Transplant, 12, pp.389~392 (2008)
  29. Kimberlin DW, "Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease", J Infect Dis, 197, pp.836~845 (2008)
  30. Acosta EP, "Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation", Clin Pharmacol Ther, 81, pp.867~872 (2007)
  31. Cocohoba JM, "Valganciclovir: an advance in cytomegalovirus therapeutics", Ann Pharmacother, 36, pp.1075~1079 (2002)
  32. Paya C, "Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients", Am J Transplant, 4, pp.611~620 (2004)
  33. Peyriere H, "Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring", Ann Pharmacother, 40, pp.143~146 (2006)
  34. Bayerl C, "Experience in treating molluscum contagiosum in children with imiquimod 5% cream", Br J Dermatol, 149(66), pp.S25~S29 (2003)
  35. Martinez MI, "Infantile hemangioma: clinical resolution with 5% imiquimod cream", Arch Dermatol, 138, pp.881~884 (2002)
  36. Berman B, "Prevention and management of hypertrophic scars and keloids after burns in children", J Craniofac Surg, 19, pp.989~1006 (2008)
  37. McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group", N Engl J Med, 339, pp.1485~1492 (1998)
  38. Di Bisceglie AM, "Hoofnagle JH. Optimal therapy of hepatitis C", Hepatology, 36(5), pp.S121~S127 (2002)
  39. Fried MW, "Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
  40. Jara P, "Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection", Pediatr Infect Dis J, 27, pp.142~148 (2008)
  41. Shah U, "Management of chronic hepatitis B in children", J Pediatr Gastroenterol Nutr, 48, pp.399~404 (2009)

관련 논문AI추천

소아에서 새로운 항진균제 요법박수은대한소아감염학회 · Pediatric Infection and Vaccine2006 · 제13권 제1호소아에서의 Quinolone계 항생제 사용의 가능성김동수, 신경미대한소아감염학회 · Pediatric Infection and Vaccine2003 · 제10권 제1호소아의 경험적 항균 요법이환종대한소아감염학회 · Pediatric Infection and Vaccine1998 · 제5권 제2호소아의 바이러스성 호흡기 감염증의 예방적 치료최은화대한소아감염학회 · Pediatric Infection and Vaccine2006 · 제13권 제1호급성 중이염의 항생제 치료박수은대한소아감염학회 · Pediatric Infection and Vaccine2002 · 제9권 제1호해외여행을 떠나는 소아들의 감염 예방김재윤대한소아감염학회 · Pediatric Infection and Vaccine2005 · 제12권 제1호

이 간행물의 다른 논문 (12건)

소아 메티실린내성 확생포도알균 감염증의 임상양상과 치료최은화pp. 1-5소아의 중이염 및 폐렴 예방을 위한 백신이환종pp. 13-23현대에서의 생백신과 이에 대한 면역반응의 재평가김경효pp. 24-30유아원에 다니는 소아의 구인강 내 수막구균 보균율과 혈청군최은화, 이환종, 이진아, 이정원, 김경효, 김남희, 강진한, 이수영, 김의종pp. 31-39열이 있는 3개월 이하의 영아에서 수막염의 예측에 대한 연구김은옥, 장영택, 송향순pp. 40-46
원문 보기